<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03543813</url>
  </required_header>
  <id_info>
    <org_study_id>CTMX-M-2029-001</org_study_id>
    <nct_id>NCT03543813</nct_id>
  </id_info>
  <brief_title>PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL</brief_title>
  <official_title>A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytomX Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytomX Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first-in-human study of CX-2029 is to characterize the safety,
      tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029
      in adult subjects with metastatic or locally advanced unresectable solid tumors or diffuse
      large B-cell lymphoma (DLBCL). PROCLAIM: PRObody CLinical Assessment In Man CX-2029 clinical
      trial 001

      PROBODY is a trademark of CytomX Therapeutics, Inc
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects experiencing a dose-limiting toxicity at various dose levels when given CX-2029 as a monotherapy</measure>
    <time_frame>21 days (dose-limiting toxicity period)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects experiencing anti-cancer activity (ORR) at various dose levels when given CX-2029 as a monotherapy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CX-2029 Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CX-2029 Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-2029 Biomarker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CX-2029 Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CX-2029 Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CX-2029 Monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX-2029</intervention_name>
    <description>CX-2029 Monotherapy</description>
    <arm_group_label>CX-2029 Biomarker</arm_group_label>
    <arm_group_label>CX-2029 Escalation</arm_group_label>
    <arm_group_label>CX-2029 Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced
             unresectable tumors

          2. Patients demonstrating disease progression after treatment with approved therapies
             that are known to confer life-prolonging benefit, or who are intolerant to or have
             declined treatment

          3. Agreement to provide mandatory archival tissue or fresh biopsy

          4. At least 18 years of age

        Exclusion Criteria:

          1. Neuropathy &gt; Grade 1

          2. Serious concurrent illness, including clinically relevant active infection

          3. Clinically significant iron metabolism disorders (eg, sickle cell anemia)

          4. Significant cardiac disease such as recent myocardial infarction

          5. History of multiple sclerosis or other demyelinating disease, Eaton-Lambert syndrome
             (para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last
             6 months, or alcoholic liver disease;

          6. Non-healing wound(s) or ulcer(s) except for ulcerative lesions caused by the
             underlying neoplasm;

          7. History of severe allergic or anaphylactic reactions to previous monoclonal antibody
             therapy;

          8. Currently receiving anticoagulation therapy with warfarin;

          9. Major surgery (requiring general anesthesia) within 3 months prior to dosing.

         10. Hepatic impairment which is moderate (Child-Pugh B) or severe (Child-Pugh C)

         11. Transfusion dependent anemia with transfusion dependency of â‰¥3 months

         12. Use of iron chelators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jana Waldes, MD</last_name>
    <role>Study Director</role>
    <affiliation>CytomX Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lori Carman</last_name>
    <phone>650-515-4267</phone>
    <email>clinicaltrials@cytomx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 21, 2018</study_first_submitted>
  <study_first_submitted_qc>May 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>solid tumor</keyword>
  <keyword>DLBCL</keyword>
  <keyword>CX-2029</keyword>
  <keyword>PROBODYâ„¢ Therapeutic</keyword>
  <keyword>Drug Conjugate</keyword>
  <keyword>Antibody drug conjugate</keyword>
  <keyword>CD71</keyword>
  <keyword>Transferrin receptor 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

